Kentucky researchers push earlier detection for focal mucoid placentitis

A new update from the University of Kentucky is putting focal mucoid placentitis back on the radar for equine reproductive practice, not because the disease is newly discovered, but because researchers say the field may finally be inching toward better diagnostics and more rational treatment. In a May 17, 2026, article in Equine Disease Quarterly published by The Horse, Hossam El‑Sheikh Ali outlined ongoing work aimed at developing a blood-based screening test and identifying therapies that can better reach the lesion site in affected placentas. (thehorse.com)

FMP, previously referred to as nocardioform placentitis, has challenged clinicians for decades. The disease was first identified in 1985 and has appeared in episodic outbreaks, including reported surges in 1998, 1999, 2011, 2017, and 2020, with the latest major activity noted in Central Kentucky and the Mid-Atlantic. Unlike ascending placentitis, which typically enters through the cervix, FMP produces sharply demarcated mucoid lesions near the base of the uterine horns, and its route of infection remains unclear. Researchers have associated it with organisms including Crossiella equi and Amycolatopsis species, but experimental inoculation studies have failed to reliably reproduce disease, leaving pathogenesis unresolved. (thehorse.com)

That uncertainty has clinical consequences. According to the Kentucky team, transabdominal ultrasound remains the main diagnostic tool, but it can miss small or early lesions because only a limited portion of the large pregnant uterus can be visualized. Their proposed answer is proteomics: profiling circulating proteins in mare blood to find a biomarker panel that distinguishes FMP cases from healthy pregnancies. The researchers say preliminary studies have already identified altered proteins and that they’re now working to verify and validate the markers with attention to sensitivity, specificity, and overall diagnostic accuracy. (thehorse.com)

On the treatment side, the message is more cautious than celebratory. El‑Sheikh Ali notes that current protocols are still largely empirical, in part because clinicians don’t yet know which drugs reliably penetrate the thick mucoid material covering lesions. Work led by Dr. Rebecca Ruby at the UK Veterinary Diagnostic Laboratory is focused on measuring antibiotic penetration at the target site, while parallel RNA-sequencing work is examining inflammatory signaling, including Toll-like receptors, that could eventually support more targeted adjunctive therapy. That matters because broader placentitis literature has long shown that many add-on therapies in mares have limited evidence, and prolonged antimicrobial treatment may suppress, rather than fully eliminate, infection. (thehorse.com)

Recent outcome data help put the stakes in perspective. In a prospective farm cohort published in Clinical Theriogenology, focal mucoid placentitis was diagnosed in 36 of 162 mares during a 2020 outbreak. Six foals from affected mares died at birth, and viability was lower than in unaffected mares. Surviving foals from affected pregnancies were lighter at birth, received slightly lower-quality colostrum, and had substantially lower IgG concentrations. At the same time, the study found that postnatal survival, later sale values, and racing performance were not significantly different among survivors, suggesting the disease’s effects may be concentrated around late gestation, parturition, and the immediate neonatal window. (clinicaltheriogenology.net)

There doesn’t appear to be much independent outside commentary yet on this specific 2026 update, but the broader industry perspective is consistent: FMP is both economically important and frustratingly opaque. Reviews and reference texts describe placentitis as a significant cause of late-term abortion, premature delivery, and neonatal compromise in mares, while FMP in particular has been tied to focal ventral placental lesions and weak or growth-retarded foals. The Kentucky group also points to a recurring environmental pattern, noting that outbreaks have often followed unusually warm, dry late summers, though that remains an observed association rather than a proven cause. (merckvetmanual.com)

Why it matters: For veterinary professionals, this story is less about a practice-changing product launch and more about a possible shift in how high-risk pregnancies may eventually be managed. If a blood-based test can be validated, it could help clinicians identify at-risk mares before ultrasound findings become obvious, giving them a better chance to intervene earlier and counsel pet parents and breeding operations more precisely. Just as important, antibiotic penetration work could begin to sort evidence-based therapy from habit, which is especially relevant in a condition where treatment has often been guided by experience rather than clear pharmacologic data. (thehorse.com)

What to watch: The next milestones are validation of the biomarker panel, publication of antibiotic penetration findings, and any prospective field studies showing whether those tools improve live foal rates, neonatal health, or treatment standardization across referral and ambulatory practice. The Kentucky team is also asking industry participants to submit blood samples, placentas, and detailed mare histories, which suggests multicenter or larger observational datasets may be part of what comes next. (thehorse.com)